title: Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers.
abstract: Lymphocyte binding to specialized high-endothelial venules (HEV) in lymph nodes and Peyer's patches is the first step in normal lymphocyte emigration and recirculation. The development and maintenance of HEV in these lymphoid organs are thought to be immunologically controlled. Because postcapillary venules in chronic inflammatory tissue often resemble the HEV of lymphoid tissue and may also be a site of lymphocyte emigration, examination of the effects of immunologic and inflammatory mediators on endothelial cells (EC) may provide important information about the physiology of both normal lymphocyte recirculation and chronic inflammation. It is reported here that treatment of human umbilical vein EC monolayers in vitro with affinity-purified human interleukin 1 (IL 1) markedly enhances the binding of both B and T lymphocytes. Increased binding was observed within 1 h of treatment of EC with as little as 0.04 U/ml IL 1. This effect of IL 1 was EC-specific, because pretreatment of T cells or human skin fibroblasts with IL 1 did not increase the binding of lymphocytes. Stimulation of binding required active EC metabolism because incubation of EC with IL 1 at 4 degrees C, or prior fixation of EC, prevented enhanced binding. The action of IL 1 was not associated with EC damage. The secretion of IL 1 by macrophages and perhaps other cells in inflammatory lesions may exert a positive feedback signal on EC to enhance further emigration of lymphocytes into the inflammatory focus.
authors.forename: D E
authors.initials: DE
authors.lastname: Cavender
authors.forename: D O
authors.initials: DO
authors.lastname: Haskard
authors.forename: B
authors.initials: B
authors.lastname: Joseph
authors.forename: M
authors.initials: M
authors.lastname: Ziff
mesh_terms: D000954:Antigens, Surface / Q000502:physiology; D001402:B-Lymphocytes / Q000378:metabolism*; D001665:Binding Sites / Q000187:drug effects; D015815:Cell Adhesion Molecules; D002478:Cells, Cultured; D004306:Dose-Response Relationship, Immunologic; D004357:Drug Synergism; D004727:Endothelium / Q000166:cytology / Q000378:metabolism*; D004731:Endotoxins / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism; D005404:Fixatives / Q000494:pharmacology; D006801:Humans; D007231:Infant, Newborn; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000502:physiology*; D007700:Kinetics; D011112:Polymyxin B / Q000494:pharmacology; D013601:T-Lymphocytes / Q000378:metabolism*; D013696:Temperature; D014470:Umbilical Cord
chemical_list: D000954:Antigens, Surface; D015815:Cell Adhesion Molecules; D004731:Endotoxins; D005404:Fixatives; D007375:Interleukin-1; D007371:Interferon-gamma; D011112:Polymyxin B